2026 Q2 - tulosraportti
34 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sittenStock status. It's starting to get tight if a batch of Weeco Astrum10/10 isn't released soon (I expect Stenocare has sent a batch on its way). Now the pharmacy in Hamburg reports sold out. The positive thing is that it shows that sales are still occurring in Germany. Well, we have been aware that Weeco Astrum10/10 has been sold out at several pharmacies since July 30, 2026, and that the pharmacies that have permission to do so have purchased internally. So we must expect a company announcement in about a month, stating that there are problems with delivery, and maybe we will get the completely correct reason. So we won't have to guess at a reason for this, which might be wrong.
Written by 3D under Bioporto but it concerns Stenocare. It shows quite well how "news" is mindlessly pumped into the debate without a critical filter. Remember to be critical of sources when you read here. It only makes me smarter about your investment - it doesn't make your investment better or worse if you increase your knowledge. " Stock status. It's starting to get tight if a batch of Weeco Astrum10/10 isn't released soon (I expect Stenocare has sent a batch). Now the pharmacy in Hamburg reports sold out. The positive thing is that it shows that sales are still occurring in Germany. Well, we have been aware that several pharmacies have been sold out of Weeco Astrum10/10 since July 30, 2026, and that pharmacies with permission to do so have bought internally. So we must expect a company announcement in about a month, stating that there are delivery problems, and maybe we will get the completely correct reason. So we won't have to guess at a reason for this, which might be wrong.- ·18.9.Once again, KDIGO's recommendations are highlighted in Bioporto`s sales promotion. From guidelines to clinical practice, AKI is a main focus at the XXXIII Congresso Brasileiro de Nefrologia in Belo Horizonte. The scientific program includes dedicated discussions on the latest KDIGO perspectives as well as presentations on AKI biomarkers https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
·16.9.Today's update from DNB Carnegie: Maintains Fair value: DKK0.50–3.00 BioPorto has announced the enrolment of its first patient in the validation trial for ProNephro NGAL in US adults. The trial is expected to enrol ~900 patients across multiple sites. Thus, we see the clinical trial as well on track, with expected readout in H2 2027. As the next potential catalyst, we expect a decision on KDIGO guidelines in Q4 2026. First patient enrolled in ProNephro NGAL validation trial. BioPorto today announced the successfully enrolment of its first patient in the validation trial for ProNephro NGAL in US adults (NCT07751913). The trial is expected to enrol ~900 patients across multiple sites in the US, versus ~500 patients in the cut-off trial. We see the clinical trial as well on track and expect a data readout in H2 2027. KDIGO guidelines likely published in Q4 2026. We expect a decision on KDIGO guidelines for NGAL biomarker tests as early as Q4 2026. Based on KDIGO’s public acute kidney injury (AKI) review, we still consider inclusion as likely, which in our view would provide validation of ProNephro and support broader clinical adoption. ProNephro is already FDA approved for paediatric use, CE-marked internationally, and globally available for RSUO, while we expect adult FDA approval in 2027. For the adult indication alone, we apply a 90% probability of approval and forecast a 27.9% CAGR 2028–45e, with a risk-adjusted NPV of DKK1.8 per share. Investor event on 7 October. BioPorto has scheduled an investor event on 7 October at 15:00–17:30 CET. We expect the company to provide an update on its strategic progression, alongside a deep-dive into the clinical landscape and KDIGO guidelines. Sign up here: https://www.globenewswire.com/news-release/2026/09/14/3361128/0/en/unlocking-the-growth-invitation-to-bioporto-s-investor-meeting-on-oct-7.html.2045???? That was damn good. You definitely get a point for that. Despite numerous attempts over several years, and regardless of whether we're talking sales or stock price, your predictions have almost never been right, even with a short time horizon of 6-12 months, so now you're making a prediction 20 years ahead. See, that's damn good humor, especially in a forum where the majority have the patience and investment horizon of mayflies. You must be very tired of being confronted with your perpetual mistakes, and on that account, I must praise you for your new strategy; in 2045, hardly anyone here will remember what you said in 2026. The question is whether there will even be something called bioporto by then.- ·16.9.First patient enrolled - BioPorto has commenced enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL validation study. https://www.globenewswire.com/news-release/2026/09/16/3362848/0/en/first-patient-in-bioporto-initiates-patient-enrollment-as-part-of-the-pronephro-aki-u-s-adult-urine-ngal-validation-study.html
- ·14.9.Unleash growth - Invitation to BioPorto's investor meeting on October 7 Press release Unleash growth - Invitation to BioPorto's investor meeting on October 7 As BioPorto continues to develop its commercial strategy and leverage new clinical opportunities, we invite you to an afternoon focusing on the key drivers that can shape the company's future. At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and the path towards sustainable growth and positive cash flow. Participants will also hear independent perspectives from leading clinical experts and capital market specialists on the opportunities created by biomarker-guided diagnostics and the updated KDIGO guidelines. Key topics include: Commercial momentum and strategic priorities Update on clinical validation study for adults What the new KDIGO guidelines may mean for biomarker adoption External perspectives on BioPorto's investment case and future value drivers Live Q&A with management and guest speakers Wednesday, October 7, 2026, 15:00 – 17:30 CET (Registration from 14:30) BioPorto A/S, Tuborg Havnevej 15, 2900 Hellerup, Denmark https://forms.cloud.microsoft/pages/responsepage.aspx?id=Xh1dCXi4X0mP_hmzX13BGkSoRbmjPGNGpIQXZHmwuD9URTlTRzc1MzlHQ1ZJOVFHRVRXRlRFUVY3Ui4u&route=shorturlThere will hardly be a lack of space. And regarding KDIGO, if one is to believe your countless writings, then KDIGO's recommendations are practically already in place, and that is without any particular buying interest for the stock being registered. So when even KDIGO cannot make the price rise, then I think you are already working on a new dream?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
34 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenStock status. It's starting to get tight if a batch of Weeco Astrum10/10 isn't released soon (I expect Stenocare has sent a batch on its way). Now the pharmacy in Hamburg reports sold out. The positive thing is that it shows that sales are still occurring in Germany. Well, we have been aware that Weeco Astrum10/10 has been sold out at several pharmacies since July 30, 2026, and that the pharmacies that have permission to do so have purchased internally. So we must expect a company announcement in about a month, stating that there are problems with delivery, and maybe we will get the completely correct reason. So we won't have to guess at a reason for this, which might be wrong.Written by 3D under Bioporto but it concerns Stenocare. It shows quite well how "news" is mindlessly pumped into the debate without a critical filter. Remember to be critical of sources when you read here. It only makes me smarter about your investment - it doesn't make your investment better or worse if you increase your knowledge. " Stock status. It's starting to get tight if a batch of Weeco Astrum10/10 isn't released soon (I expect Stenocare has sent a batch). Now the pharmacy in Hamburg reports sold out. The positive thing is that it shows that sales are still occurring in Germany. Well, we have been aware that several pharmacies have been sold out of Weeco Astrum10/10 since July 30, 2026, and that pharmacies with permission to do so have bought internally. So we must expect a company announcement in about a month, stating that there are delivery problems, and maybe we will get the completely correct reason. So we won't have to guess at a reason for this, which might be wrong.
- ·18.9.Once again, KDIGO's recommendations are highlighted in Bioporto`s sales promotion. From guidelines to clinical practice, AKI is a main focus at the XXXIII Congresso Brasileiro de Nefrologia in Belo Horizonte. The scientific program includes dedicated discussions on the latest KDIGO perspectives as well as presentations on AKI biomarkers https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
- ·16.9.Today's update from DNB Carnegie: Maintains Fair value: DKK0.50–3.00 BioPorto has announced the enrolment of its first patient in the validation trial for ProNephro NGAL in US adults. The trial is expected to enrol ~900 patients across multiple sites. Thus, we see the clinical trial as well on track, with expected readout in H2 2027. As the next potential catalyst, we expect a decision on KDIGO guidelines in Q4 2026. First patient enrolled in ProNephro NGAL validation trial. BioPorto today announced the successfully enrolment of its first patient in the validation trial for ProNephro NGAL in US adults (NCT07751913). The trial is expected to enrol ~900 patients across multiple sites in the US, versus ~500 patients in the cut-off trial. We see the clinical trial as well on track and expect a data readout in H2 2027. KDIGO guidelines likely published in Q4 2026. We expect a decision on KDIGO guidelines for NGAL biomarker tests as early as Q4 2026. Based on KDIGO’s public acute kidney injury (AKI) review, we still consider inclusion as likely, which in our view would provide validation of ProNephro and support broader clinical adoption. ProNephro is already FDA approved for paediatric use, CE-marked internationally, and globally available for RSUO, while we expect adult FDA approval in 2027. For the adult indication alone, we apply a 90% probability of approval and forecast a 27.9% CAGR 2028–45e, with a risk-adjusted NPV of DKK1.8 per share. Investor event on 7 October. BioPorto has scheduled an investor event on 7 October at 15:00–17:30 CET. We expect the company to provide an update on its strategic progression, alongside a deep-dive into the clinical landscape and KDIGO guidelines. Sign up here: https://www.globenewswire.com/news-release/2026/09/14/3361128/0/en/unlocking-the-growth-invitation-to-bioporto-s-investor-meeting-on-oct-7.html.2045???? That was damn good. You definitely get a point for that. Despite numerous attempts over several years, and regardless of whether we're talking sales or stock price, your predictions have almost never been right, even with a short time horizon of 6-12 months, so now you're making a prediction 20 years ahead. See, that's damn good humor, especially in a forum where the majority have the patience and investment horizon of mayflies. You must be very tired of being confronted with your perpetual mistakes, and on that account, I must praise you for your new strategy; in 2045, hardly anyone here will remember what you said in 2026. The question is whether there will even be something called bioporto by then.
- ·16.9.First patient enrolled - BioPorto has commenced enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL validation study. https://www.globenewswire.com/news-release/2026/09/16/3362848/0/en/first-patient-in-bioporto-initiates-patient-enrollment-as-part-of-the-pronephro-aki-u-s-adult-urine-ngal-validation-study.html
- ·14.9.Unleash growth - Invitation to BioPorto's investor meeting on October 7 Press release Unleash growth - Invitation to BioPorto's investor meeting on October 7 As BioPorto continues to develop its commercial strategy and leverage new clinical opportunities, we invite you to an afternoon focusing on the key drivers that can shape the company's future. At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and the path towards sustainable growth and positive cash flow. Participants will also hear independent perspectives from leading clinical experts and capital market specialists on the opportunities created by biomarker-guided diagnostics and the updated KDIGO guidelines. Key topics include: Commercial momentum and strategic priorities Update on clinical validation study for adults What the new KDIGO guidelines may mean for biomarker adoption External perspectives on BioPorto's investment case and future value drivers Live Q&A with management and guest speakers Wednesday, October 7, 2026, 15:00 – 17:30 CET (Registration from 14:30) BioPorto A/S, Tuborg Havnevej 15, 2900 Hellerup, Denmark https://forms.cloud.microsoft/pages/responsepage.aspx?id=Xh1dCXi4X0mP_hmzX13BGkSoRbmjPGNGpIQXZHmwuD9URTlTRzc1MzlHQ1ZJOVFHRVRXRlRFUVY3Ui4u&route=shorturlThere will hardly be a lack of space. And regarding KDIGO, if one is to believe your countless writings, then KDIGO's recommendations are practically already in place, and that is without any particular buying interest for the stock being registered. So when even KDIGO cannot make the price rise, then I think you are already working on a new dream?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
34 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenStock status. It's starting to get tight if a batch of Weeco Astrum10/10 isn't released soon (I expect Stenocare has sent a batch on its way). Now the pharmacy in Hamburg reports sold out. The positive thing is that it shows that sales are still occurring in Germany. Well, we have been aware that Weeco Astrum10/10 has been sold out at several pharmacies since July 30, 2026, and that the pharmacies that have permission to do so have purchased internally. So we must expect a company announcement in about a month, stating that there are problems with delivery, and maybe we will get the completely correct reason. So we won't have to guess at a reason for this, which might be wrong.Written by 3D under Bioporto but it concerns Stenocare. It shows quite well how "news" is mindlessly pumped into the debate without a critical filter. Remember to be critical of sources when you read here. It only makes me smarter about your investment - it doesn't make your investment better or worse if you increase your knowledge. " Stock status. It's starting to get tight if a batch of Weeco Astrum10/10 isn't released soon (I expect Stenocare has sent a batch). Now the pharmacy in Hamburg reports sold out. The positive thing is that it shows that sales are still occurring in Germany. Well, we have been aware that several pharmacies have been sold out of Weeco Astrum10/10 since July 30, 2026, and that pharmacies with permission to do so have bought internally. So we must expect a company announcement in about a month, stating that there are delivery problems, and maybe we will get the completely correct reason. So we won't have to guess at a reason for this, which might be wrong.
- ·18.9.Once again, KDIGO's recommendations are highlighted in Bioporto`s sales promotion. From guidelines to clinical practice, AKI is a main focus at the XXXIII Congresso Brasileiro de Nefrologia in Belo Horizonte. The scientific program includes dedicated discussions on the latest KDIGO perspectives as well as presentations on AKI biomarkers https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
- ·16.9.Today's update from DNB Carnegie: Maintains Fair value: DKK0.50–3.00 BioPorto has announced the enrolment of its first patient in the validation trial for ProNephro NGAL in US adults. The trial is expected to enrol ~900 patients across multiple sites. Thus, we see the clinical trial as well on track, with expected readout in H2 2027. As the next potential catalyst, we expect a decision on KDIGO guidelines in Q4 2026. First patient enrolled in ProNephro NGAL validation trial. BioPorto today announced the successfully enrolment of its first patient in the validation trial for ProNephro NGAL in US adults (NCT07751913). The trial is expected to enrol ~900 patients across multiple sites in the US, versus ~500 patients in the cut-off trial. We see the clinical trial as well on track and expect a data readout in H2 2027. KDIGO guidelines likely published in Q4 2026. We expect a decision on KDIGO guidelines for NGAL biomarker tests as early as Q4 2026. Based on KDIGO’s public acute kidney injury (AKI) review, we still consider inclusion as likely, which in our view would provide validation of ProNephro and support broader clinical adoption. ProNephro is already FDA approved for paediatric use, CE-marked internationally, and globally available for RSUO, while we expect adult FDA approval in 2027. For the adult indication alone, we apply a 90% probability of approval and forecast a 27.9% CAGR 2028–45e, with a risk-adjusted NPV of DKK1.8 per share. Investor event on 7 October. BioPorto has scheduled an investor event on 7 October at 15:00–17:30 CET. We expect the company to provide an update on its strategic progression, alongside a deep-dive into the clinical landscape and KDIGO guidelines. Sign up here: https://www.globenewswire.com/news-release/2026/09/14/3361128/0/en/unlocking-the-growth-invitation-to-bioporto-s-investor-meeting-on-oct-7.html.2045???? That was damn good. You definitely get a point for that. Despite numerous attempts over several years, and regardless of whether we're talking sales or stock price, your predictions have almost never been right, even with a short time horizon of 6-12 months, so now you're making a prediction 20 years ahead. See, that's damn good humor, especially in a forum where the majority have the patience and investment horizon of mayflies. You must be very tired of being confronted with your perpetual mistakes, and on that account, I must praise you for your new strategy; in 2045, hardly anyone here will remember what you said in 2026. The question is whether there will even be something called bioporto by then.
- ·16.9.First patient enrolled - BioPorto has commenced enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL validation study. https://www.globenewswire.com/news-release/2026/09/16/3362848/0/en/first-patient-in-bioporto-initiates-patient-enrollment-as-part-of-the-pronephro-aki-u-s-adult-urine-ngal-validation-study.html
- ·14.9.Unleash growth - Invitation to BioPorto's investor meeting on October 7 Press release Unleash growth - Invitation to BioPorto's investor meeting on October 7 As BioPorto continues to develop its commercial strategy and leverage new clinical opportunities, we invite you to an afternoon focusing on the key drivers that can shape the company's future. At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and the path towards sustainable growth and positive cash flow. Participants will also hear independent perspectives from leading clinical experts and capital market specialists on the opportunities created by biomarker-guided diagnostics and the updated KDIGO guidelines. Key topics include: Commercial momentum and strategic priorities Update on clinical validation study for adults What the new KDIGO guidelines may mean for biomarker adoption External perspectives on BioPorto's investment case and future value drivers Live Q&A with management and guest speakers Wednesday, October 7, 2026, 15:00 – 17:30 CET (Registration from 14:30) BioPorto A/S, Tuborg Havnevej 15, 2900 Hellerup, Denmark https://forms.cloud.microsoft/pages/responsepage.aspx?id=Xh1dCXi4X0mP_hmzX13BGkSoRbmjPGNGpIQXZHmwuD9URTlTRzc1MzlHQ1ZJOVFHRVRXRlRFUVY3Ui4u&route=shorturlThere will hardly be a lack of space. And regarding KDIGO, if one is to believe your countless writings, then KDIGO's recommendations are practically already in place, and that is without any particular buying interest for the stock being registered. So when even KDIGO cannot make the price rise, then I think you are already working on a new dream?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt